益格卢卡贡衍生:人类生理学和治疗潜力
Lærke S Gasbjerg1,2, Casper K Nielsen1, Malte P Suppli1
1Center for Clinical Metabolic Research, Herlev and Gentofte University Hospital, Copenhagen, Denmark.
Physiological reviews
|July 28, 2025
概括
像GLP-1这样的proglucagon衍生是调节新陈代谢和食欲的关键激素. 它们为糖尿病,肥胖和短肠综合征提供了重要的治疗应用.
科学领域:
- 内分泌学和新陈代谢学
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 益葡萄糖衍生 (PGDPs) 是调节葡萄糖,脂质和蛋白质代谢,食欲和胃肠功能的关键激素.
- PGDPs,包括葡萄糖,葡萄糖类1 (GLP-1),葡萄糖类2 (GLP-2),和oxyntomodulin,通过不同的G蛋白结合受体起作用.
- 这些在内分泌,神经内分泌和新陈代谢过程中起着重要作用,成为核心治疗点.
研究的目的:
- 审查PGDPs的人类生理学.
- 探索PGDPs在病理生理学的参与.
- 讨论PGDPs和相关受体激动剂的当前和未来的治疗应用.
主要方法:
- 临床审查现有关于前葡萄糖衍生的文献.
- 分析生理作用,病理生理参与和治疗应用.
- 讨论单受体和多受体激动剂的进展和未来的前景.
主要成果:
- 葡萄糖是用于治疗低血糖症的.
- GLP-1受体激动剂通过降低葡萄糖,抑制食欲和心脏保护作用改变了2型糖尿病和肥胖管理.
- GLP-2类似物为短肠综合征提供了向治疗.
结论:
- PGDPs是人类生理学的重要调节者,具有显著的治疗潜力.
- 受体激动剂的进步为代谢和胃肠道疾病提供了改进的治疗策略.
- 未来的研究有望为涉及PGDPs的新疗法和组合疗法提供希望.
相关概念视频
Glucagon-like Receptor Agonists
420
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
420
Hypoglycemia and Glucagon
338
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
338
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K
Hormones Regulating Blood Glucose
4.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.0K
Insulin: Biosynthesis, Chemistry, and Preparation
554
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
554
Dipeptidyl Peptidase 4 Inhibitors
261
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
261


